INVANZ was as effective as ceftriaxone or piperacillin/ tazobactam in abdominal infections, community-acquired pneumonia, gynaecological infections and diabetic foot infections: the same cure rates were reached for both INVANZ and the comparator medicine (between 87 and 94% for INVANZ, against 83 to 92% for the comparators).